Prospective phase I study of nivolumab to promote graft-versus-tumour in relapsed or refractory haematological malignancy post allogeneic haematopoietic stem cell transplantation.
Patients receiving immunotherapy after stem cell transplant who develop specific immune responses show earlier signs of cancer control.
This phase i clinical trial examined Prospective phase I study of nivolumab to promote graft-versus-tumour in relapsed or refractory haematological malignancy post allogeneic haematopoietic stem cell transplantation. The PubMed abstract reports that Patients who developed GVHD had higher T-cell activation at baseline and achieved early clinical responses.
What the study was
- Study design
- Phase I clinical trial
- Population
- patients with relapsed/refractory haematological malignancies post-alloHSCT received nivolumab every 2 weeks
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- British journal of haematology
Why it surfaced
Score 5/10 reflects phase i clinical trial evidence with abstract only access; genuine match to Novel therapeutics: immunotherapy, CAR-T, targeted therapy.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.